title: Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial.
authors.forename: S A
authors.initials: SA
authors.lastname: Evensen
authors.forename: F
authors.initials: F
authors.lastname: Wisløff
authors.forename: E
authors.initials: E
authors.lastname: Müller
authors.forename: I
authors.initials: I
authors.lastname: Talstad
authors.forename: A
authors.initials: A
authors.lastname: Waage
authors.forename: L
authors.initials: L
authors.lastname: Johansen
mesh_terms: D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin